News & Updates

A polypill comprising ultra-low doses of four antihypertensive drugs shows promise in reducing blood pressure (BP) levels compared with standard monotherapy, according to a small study presented at AHA 2022.

Edaravone appears to be safe and effective in the treatment of patients with ischaemic stroke, yielding improvements in activities of daily living and neurologic deficits in the short term, a study has found.

Erenumab proves to be effective at lowering the number of monthly migraine days in Asian patients with chronic migraine while having a favourable safety profile, according to the results of DRAGON study.

Low intake of dietary choline may increase the risk of incident dementia and Alzheimer’s disease (AD), a recent study has found.

There appears to be no longitudinal association between hair cortisol and cortisone levels with dementia and various measures of cognitive function, a recent study has found.

Lecanemab reduces brain amyloid burden and offers moderate slowing of cognitive decline in early Alzheimer’s disease (AD), but is associated with adverse events (AEs), according to the results of the phase III, double-blind, placebo-controlled CLARITY AD trial, presented at the 15^th Clinical Trials on Alzheimer’s Disease (CTAD 2022) conference.

Researchers from the University of Hong Kong (HKU) report that the incidence of “young stroke” (ie, strokes occurring in those aged 18–55 years) has increased by 30 percent in Hong Kong’s residents since 2001.

Among adults with autism spectrum disorder (ASD), group-based cognitive behavioural therapy (CBT) appears to yield modest improvements in emotion regulation, a recent study has found.